Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01841463
Title Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Piramal Enterprises Limited
Indications

melanoma

Therapies

Vemurafenib + Voruciclib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCSF Medical Center at Mount Zion South San Francisco California 94115 United States Details
University of Colorado Anschutz Medical Campus Aurora Colorado 80045 United States Details
Georgetown-Lombardi Comprehensive Cancer Ctr Washington District of Columbia 20057 United States Details
The University of Texas, MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field